{"id":79978,"date":"2026-06-09T08:57:46","date_gmt":"2026-06-09T08:57:46","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/79978\/"},"modified":"2026-06-09T08:57:46","modified_gmt":"2026-06-09T08:57:46","slug":"roche-to-pay-nurix-as-much-as-us2-3-bil-in-cancer-drug-deal-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/79978\/","title":{"rendered":"Roche to pay Nurix as much as US$2.3 bil in cancer drug deal"},"content":{"rendered":"

\"\" <\/p>\n

The collaboration adds to Roche\u2019s push to bolster its cancer portfolio, as it seeks new drivers of growth beyond aging blockbuster medicines.<\/p>\n

(JUne 8): Roche Holding AG agreed to pay Nurix Therapeutics Inc as much as US$2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose disease stops responding to existing treatments.<\/p>\n

Under the deal announced Monday, Nurix will receive US$700 million upfront for bexobrutideg, a pill being developed for certain blood cancers and potentially other immune-system and neurological diseases. Roche and Nurix will share development costs and split US profits equally, while Roche will commercialise the therapy outside the US.<\/p>\n

The agreement gives Roche access to a so-called BTK degrader, a new class of medicines aimed at eliminating a protein that drives several blood cancers. The companies said the drug could offer an advantage over current BTK inhibitors by potentially overcoming resistance mutations that emerge during treatment.<\/p>\n

The collaboration adds to Roche\u2019s push to bolster its cancer portfolio, as it seeks new drivers of growth beyond aging blockbuster medicines. The companies expect the transaction to close in the third quarter of 2026.<\/p>\n

Roche shares fell as much as 1.4% in early trading in Zurich.<\/p>\n

See Also:<\/p>\n","protected":false},"excerpt":{"rendered":"The collaboration adds to Roche\u2019s push to bolster its cancer portfolio, as it seeks new drivers of growth…\n","protected":false},"author":2,"featured_media":79979,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[27690,2112,41514,134],"class_list":["post-79978","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-blood-cancers","tag-cancer","tag-nurix-therapeutics-inc","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116719324244807377","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=79978"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/79979"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=79978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=79978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=79978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}